FluoroType® EBV

Epstein-Barr virus

HAIN LIFESCIENCE
A Bruker Company

Your molecular genetic test system for quantitative detection of Epstein-Barr virus from EDTA plasma.

Your benefits of using FluoroType® EBV

- **Reliable quantification:** Viral load assessment in IU/ml (WHO International Standard) requires only two quantification standards. Virus concentrations beyond the limit of quantification are evaluated as qualitative results.
- **User-friendly:** Minimal hands-on time with automated DNA extraction for an efficient workflow. Quantification standards need to be recorded only once per kit lot. Interpretation of results is performed automatically by the **FluoroSoftware**.
- **Fast and dependable results:** Internal controls monitor test performance from sample preparation to amplification and detection. Reliable test results are available within only three hours.
- **Maximum flexibility:** A universal test protocol allows combination with further parameters of our virology portfolio. Single samples as well as high sample numbers can be analyzed efficiently according to your needs.
- **CE-marked:** No need for elaborate validation studies.

Epstein-Barr virus

With a worldwide prevalence exceeding 90 %, Epstein-Barr virus (EBV) is spread widely among the adult human population. Virus transmission primarily occurs via saliva. Primary infection with EBV in early childhood is usually asymptomatic, whereas later infection in adolescence or adulthood may cause infectious mononucleosis (kissing disease). EBV mainly infects B cells, in which the virus establishes lifelong persistence. Due to its transforming capacity, EBV is classified carcinogenic to humans (class I carcinogen). Numerous malignancies (e. g. Burkitt's lymphoma, Hodgkin's lymphoma or post-transplant lymphoproliferative disorder (PT-LPD)) have been linked to EBV-reactivation, which may be caused for instance by immune deficiency.

Fast and reliable diagnostics with FluoroType® EBV

Close monitoring of EB viral load is of utmost importance in order to identify and evaluate potential virus reactivation at an early stage, especially in risk patients.

Test principle FluoroType® EBV

DNA extraction from EDTA plasma

Amplification and detection

Results in approx. 3 hours

Innovative Technology

Viral DNA is extracted automatically from EDTA plasma with the **GenoXtract®** instrument followed by amplification, detection and quantification of characteristic target sequences with real-time PCR using the **FluoroCycler®** instruments. Internal controls monitor test performance from sample preparation to test result. Reliable EB viral load assessment in International Units (IU/ml according to NIBSC WHO International Standard) requires only two quantification standards, which are determined only once per kit lot, eliminating the need for standard measurements with each run. Additionally, virus concentrations beyond linear quantification range are evaluated as qualitative results. Interpretation of results is performed automatically by the **FluoroSoftware**, for reliable test results within only three hours.

For further information please contact Hain Lifescience or your local distributor!

L_JN0419028_0719

Hain Lifescience GmbH
Hardwiesenstrasse 1 | 72147 Nehren | Germany
Tel.: +49 (0) 74 73- 94 51- 0 | Fax: +49 (0) 74 73- 94 51- 31
E-Mail: info@hain-lifescience.de | www.hain-lifescience.de

HAIN LIFESCIENCE
A Bruker Company